Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (111-120 of 211) with videos related to

Pageof 22
Sort By:
Cancer Research|October 3, 2003
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
Blood|August 5, 2009
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progressionJui Dutta-Simmons, Yunyu Zhang, Gullu Gorgun, et al.
Cancer Research|March 15, 2024
Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3'-Kinase/AKT SignalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
Blood|April 30, 2016
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentYu-Tzu Tai, Chirag Acharya, Gang An, et al.
Blood|July 24, 2010
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Ender Soydan, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 ExpressionLijie Xing, Su Wang, Jiye Liu, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2019
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple MyelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Cancer Cell|October 6, 2009
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic targetDharminder Chauhan, Ajita V Singh, Mohan Brahmandam, et al.
Pageof 22

Showing results (111-120 of 211) with videos related to

Sort By:
Pageof 22
Cancer Research|October 3, 2003
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
Blood|August 5, 2009
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progressionJui Dutta-Simmons, Yunyu Zhang, Gullu Gorgun, et al.
Cancer Research|March 15, 2024
Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of β1-Integrin and Phosphatidylinositol 3'-Kinase/AKT SignalingYu-Tzu Tai, Klaus Podar, Laurence Catley, et al.
Blood|April 30, 2016
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentYu-Tzu Tai, Chirag Acharya, Gang An, et al.
Blood|July 24, 2010
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Ender Soydan, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 ExpressionLijie Xing, Su Wang, Jiye Liu, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2019
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple MyelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Cancer Cell|October 6, 2009
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic targetDharminder Chauhan, Ajita V Singh, Mohan Brahmandam, et al.
Pageof 22